Follow us on:

Linkedin Facebook

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

One Health Group

One Health Group reports strong trading and progress on surgical hub development

One Health Group has confirmed that trading for the year to date remains in line with expectations, with continued organic growth and progress on its first Surgical Hub in Scunthorpe. The company will provide a further trading update for the six months to 30 September 2025 in late October...

Roquefort Therapeutics secures exclusivity with Coiled Therapeutics RTO, eyeing AIM relist and NASDAQ (Video)

Executive Chairman Stephen West explains how AO-252, Coiled’s first-in-class oncology asset, could reshape Roquefort’s pipeline, transform shareholder value, and set the stage for an AIM relist with an eye on NASDAQ..
Aptamer

Aptamer signs contract with Metir for Cryptosporidium detection binders

Aptamer has signed a new contract with Metir plc to develop Optimer® binders for the rapid detection of Cryptosporidium parvum oocysts in Metir’s Pathogen Detector platform...
One Health Group

One Health Group shortlisted for two prestigious awards at the 30th anniversary AIM Awards

Sheffield-headquartered One Health Group plc (LON:OHGR), an independent provider of NHS-funded medical procedures, is delighted to announce that it has been shortlisted for two categories..
Roquefort Therapeutics

Roquefort Therapeutics plc plans transformational acquisition into clinical stage biotech company (LON:ROQ)

Roquefort Therapeutics has signed Heads of Terms to acquire 100% of Coiled Therapeutics, Inc. in a reverse takeover valued at £30 million, payable in shares. Coiled USA, a spin-out from A2A Pharmaceuticals, holds exclusive worldwide rights to AO-252, a first-in-class cancer therapy currently in Phase I trials in the United States...
Physicians Capital

Physicians turning professional insight into real estate advantage

Doctors are using their unique knowledge of healthcare operations to transform medical real estate into a source of stability and long-term independence...
Hutchmed

HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653...
Genus plc

Genus accelerates China joint venture with BCA to advance PRRS resistant pig

Genus plc has agreed updated terms with Beijing Capital Agribusiness to fast-track the formation of a porcine joint venture in China. The deal secures a US$160m cash payment, milestone income, and future royalties, while positioning PIC China to commercialise PRRS resistant pigs with stronger local backing...
Aptamer Group

Aptamer signs therapeutic development deal with Invizius

Aptamer Group has entered a new agreement with Invizius to develop Optimer® binders targeting the complement system for inflammatory and autoimmune diseases. The collaboration aims to enhance Invizius’ H-Guard® platform, currently in Phase 2 trials, by providing safer and more precise therapies, including potential treatments for IgA nephropathy...
EDX Medical

EDX Medical confirms date for 2025 Annual General Meeting

EDX Medical will hold its AGM on 29 September 2025 at 2:00 p.m. at the Marcus Beck Library, Royal School of Medicine, London. The meeting will cover standard business matters and provide shareholders with an update on company progress...
Hutchmed

HUTCHMED CEO Dr Weiguo Su takes leave of absence

HUTCHMED (China) has announced that Chief Executive Officer Dr Weiguo Su will take a leave of absence due to health reasons. The Board has appointed Johnny Cheng, the company’s Chief Financial Officer and Executive Director, as Acting CEO while continuing in his CFO role...
EDX Medical Group plc

EDX Medical reports 2025 results and advances in cancer diagnostics

EDX Medical Group has published its Annual Report for the year ending 31 March 2025, highlighting the development of a new AI-driven prostate cancer test, a £3 million fundraising, expanded European partnerships, and a service agreement with Royal Marsden NHS Foundation Trust...
Aptamer Group

Aptamer advances enzyme modulation projects and expands pharma collaboration

Aptamer Group announced progress on its Optimer® enzyme modulation projects, including a 10-year non-exclusive licensing deal forecast to cover around 15% of annual overheads and further agreements under discussion with global enzyme distributors...
Convatec Group

Convatec Group Plc launches $300m share buyback programme

Convatec has announced a non-discretionary share buyback of up to $300 million to return surplus capital to shareholders. The programme, managed by UBS AG London Branch, will run until 31 December 2025 and aims to reduce the company’s share capital, with purchased shares either cancelled or held in treasury for employee plans...
Hutchmed

HUTCHMED completes enrollment for phase III SANOVO lung cancer study

HUTCHMED has completed patient enrollment for its Phase III SANOVO trial evaluating ORPATHYS® (savolitinib) with TAGRISSO® (osimertinib) as a first-line treatment for certain EGFR-mutated, MET-overexpressed non-small cell lung cancer patients...
Cizzle Bio

Cizzle Biotechnology to launch CIZ1B cancer test across USA

Cizzle Biotechnology has announced that its North American partner, Cizzle Bio Inc, has signed an agreement with a multi-site accredited laboratory group to roll out the CIZ1B biomarker test for early lung cancer detection across the USA...
Aptamer Group

Aptamer secures contract Eetension with top 5 pharma partner

Aptamer has extended its collaboration with a top 5 global pharmaceutical company to advance Optimer® binders into a fully functional ELISA assay. The agreement builds on the successful completion of the initial binder development phase, with Aptamer retaining IP ownership to support future commercialisation opportunities...
EDX Medical Group plc

Sir Chris Evans on EDX Medical’s partnership to develop rapid pneumonia test (AQSE:EDX)

EDX Medical has teamed up with Cambridge University Hospital's NHS Foundation Trust, the UK Health Security Agency, and other Cambridge institutions to create a rapid digital diagnostic for hospital-acquired pneumonia. The collaboration aims to deliver a reliable test that could save lives, reduce NHS costs, and improve patient outcomes, with development expected to complete later this year...
EDX Medical Group plc

EDX Medical Group: Pioneering the Future of Digital Diagnostics – Oberon Capital

EDX Medical is redefining diagnostics with cutting-edge cancer ‘Super Tests’, rapid sepsis detection & AI-powered pneumonia testing...

EDX Medical Group targets NHS pneumonia cases with breakthrough rapid test partnership (Video)

EDX Medical Group Plc has joined forces with leading NHS and government health bodies to deliver a rapid hospital-acquired pneumonia test. Sir Chris Evans explains why this partnership could change patient outcomes, cut costs, and accelerate the UK’s precision medicine agenda...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

November 24, 2025

One Health Group

One Health Group reports strong trading and progress on surgical hub development

One Health Group has confirmed that trading for the year to date remains in line with expectations, with continued organic growth and progress on its first Surgical Hub in Scunthorpe. The company will provide a further trading update for the six months to 30 September 2025 in late October...

Roquefort Therapeutics secures exclusivity with Coiled Therapeutics RTO, eyeing AIM relist and NASDAQ (Video)

Executive Chairman Stephen West explains how AO-252, Coiled’s first-in-class oncology asset, could reshape Roquefort’s pipeline, transform shareholder value, and set the stage for an AIM relist with an eye on NASDAQ..
Aptamer

Aptamer signs contract with Metir for Cryptosporidium detection binders

Aptamer has signed a new contract with Metir plc to develop Optimer® binders for the rapid detection of Cryptosporidium parvum oocysts in Metir’s Pathogen Detector platform...
One Health Group

One Health Group shortlisted for two prestigious awards at the 30th anniversary AIM Awards

Sheffield-headquartered One Health Group plc (LON:OHGR), an independent provider of NHS-funded medical procedures, is delighted to announce that it has been shortlisted for two categories..
Roquefort Therapeutics

Roquefort Therapeutics plc plans transformational acquisition into clinical stage biotech company (LON:ROQ)

Roquefort Therapeutics has signed Heads of Terms to acquire 100% of Coiled Therapeutics, Inc. in a reverse takeover valued at £30 million, payable in shares. Coiled USA, a spin-out from A2A Pharmaceuticals, holds exclusive worldwide rights to AO-252, a first-in-class cancer therapy currently in Phase I trials in the United States...
Physicians Capital

Physicians turning professional insight into real estate advantage

Doctors are using their unique knowledge of healthcare operations to transform medical real estate into a source of stability and long-term independence...
Hutchmed

HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653...
Genus plc

Genus accelerates China joint venture with BCA to advance PRRS resistant pig

Genus plc has agreed updated terms with Beijing Capital Agribusiness to fast-track the formation of a porcine joint venture in China. The deal secures a US$160m cash payment, milestone income, and future royalties, while positioning PIC China to commercialise PRRS resistant pigs with stronger local backing...
Aptamer Group

Aptamer signs therapeutic development deal with Invizius

Aptamer Group has entered a new agreement with Invizius to develop Optimer® binders targeting the complement system for inflammatory and autoimmune diseases. The collaboration aims to enhance Invizius’ H-Guard® platform, currently in Phase 2 trials, by providing safer and more precise therapies, including potential treatments for IgA nephropathy...
EDX Medical

EDX Medical confirms date for 2025 Annual General Meeting

EDX Medical will hold its AGM on 29 September 2025 at 2:00 p.m. at the Marcus Beck Library, Royal School of Medicine, London. The meeting will cover standard business matters and provide shareholders with an update on company progress...
Hutchmed

HUTCHMED CEO Dr Weiguo Su takes leave of absence

HUTCHMED (China) has announced that Chief Executive Officer Dr Weiguo Su will take a leave of absence due to health reasons. The Board has appointed Johnny Cheng, the company’s Chief Financial Officer and Executive Director, as Acting CEO while continuing in his CFO role...
EDX Medical Group plc

EDX Medical reports 2025 results and advances in cancer diagnostics

EDX Medical Group has published its Annual Report for the year ending 31 March 2025, highlighting the development of a new AI-driven prostate cancer test, a £3 million fundraising, expanded European partnerships, and a service agreement with Royal Marsden NHS Foundation Trust...
Aptamer Group

Aptamer advances enzyme modulation projects and expands pharma collaboration

Aptamer Group announced progress on its Optimer® enzyme modulation projects, including a 10-year non-exclusive licensing deal forecast to cover around 15% of annual overheads and further agreements under discussion with global enzyme distributors...
Convatec Group

Convatec Group Plc launches $300m share buyback programme

Convatec has announced a non-discretionary share buyback of up to $300 million to return surplus capital to shareholders. The programme, managed by UBS AG London Branch, will run until 31 December 2025 and aims to reduce the company’s share capital, with purchased shares either cancelled or held in treasury for employee plans...
Hutchmed

HUTCHMED completes enrollment for phase III SANOVO lung cancer study

HUTCHMED has completed patient enrollment for its Phase III SANOVO trial evaluating ORPATHYS® (savolitinib) with TAGRISSO® (osimertinib) as a first-line treatment for certain EGFR-mutated, MET-overexpressed non-small cell lung cancer patients...
Cizzle Bio

Cizzle Biotechnology to launch CIZ1B cancer test across USA

Cizzle Biotechnology has announced that its North American partner, Cizzle Bio Inc, has signed an agreement with a multi-site accredited laboratory group to roll out the CIZ1B biomarker test for early lung cancer detection across the USA...
Aptamer Group

Aptamer secures contract Eetension with top 5 pharma partner

Aptamer has extended its collaboration with a top 5 global pharmaceutical company to advance Optimer® binders into a fully functional ELISA assay. The agreement builds on the successful completion of the initial binder development phase, with Aptamer retaining IP ownership to support future commercialisation opportunities...
EDX Medical Group plc

Sir Chris Evans on EDX Medical’s partnership to develop rapid pneumonia test (AQSE:EDX)

EDX Medical has teamed up with Cambridge University Hospital's NHS Foundation Trust, the UK Health Security Agency, and other Cambridge institutions to create a rapid digital diagnostic for hospital-acquired pneumonia. The collaboration aims to deliver a reliable test that could save lives, reduce NHS costs, and improve patient outcomes, with development expected to complete later this year...
EDX Medical Group plc

EDX Medical Group: Pioneering the Future of Digital Diagnostics – Oberon Capital

EDX Medical is redefining diagnostics with cutting-edge cancer ‘Super Tests’, rapid sepsis detection & AI-powered pneumonia testing...

EDX Medical Group targets NHS pneumonia cases with breakthrough rapid test partnership (Video)

EDX Medical Group Plc has joined forces with leading NHS and government health bodies to deliver a rapid hospital-acquired pneumonia test. Sir Chris Evans explains why this partnership could change patient outcomes, cut costs, and accelerate the UK’s precision medicine agenda...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple